ChromoCure, Inc. Announces Elimination of $800,000 of Debt With Cyberhand Asset Sale

VANCOUVER, BC--(Marketwire - September 09, 2009) -

ChromoCure, Inc. (PINKSHEETS: KKUR) announced today it executed an Asset Purchase Agreement with certain secured creditors owning $800,000 of company debt. The debt is secured by all of the assets of the prior “Cyberhand” operations. The Company and the creditors have agreed to exchange these assets for complete elimination of the debt.

As previously announced, it is the intention of the creditors to establish new operations with the Cyberhand assets and distribute stock in the new company, pro rata, to all prior stockholders of Cyberhand. ChromoCure has agreed to supply the new company with all shareholder information for the planned stock distribution.

The transaction structure was specifically designed to eliminate long-term liabilities. The elimination of this long-term liability releases the company from its secured debt obligation and improves shareholder equity.

Elimination of this Note removes substantially all of the company’s long-term liabilities and leaves the company comparatively debt-free.

Updates will be timely published on the following:

-- Announcement of joint research and development agreement -- Initial scanner installations with diagnostic labs -- Elimination of significant long-term liabilities and removal from the Balance Sheet -- Additional appointments to the Company’s Advisory Boards -- Acquisition of profitable labs to expand the company’s operations -- Release of technology and industry White Papers 

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company’s systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology is superior and will become the gold standard for cancer detection worldwide.

The Company’s technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company’s filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.